Claims for Patent: 5,683,906

Summary for Patent: 5,683,906

Title:	Preparation of immortalized cells
Abstract:	Cell lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes and hepatocytes. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.
Inventor(s):	Moore; Emma E. (Seattle, WA)
Assignee:	ZymoGenetics, Inc. (Seattle, WA)
Application Number:	08/303,983
Patent Claims:	1. A method of preparing immortalized cell lines of an osteoclast lineage or of an osteoblast lineage comprising the steps of: culturing bone tissue or bone marrow tissue from a p53 growth suppressor gene deficient mouse in a growth medium isolating component cells from the cultured tissue; assaying a least a portion of the isolated component cells for expression of a set of differentiation markers expressed by a cell of an osteoclast or osteoblast lineage thereby identifying a subset of said isolated cells; and selectively culturing said subset of cells expressing said set of differentiation markers wherein said subset of cells are osteoclast lineage or osteoblast lineage cells and said set of differentiation markers include Mac-1 expression and non-specific esterase expression for osteoclast lineage cells and include alkaline phosphatase expression, parathyroid hormone-induced cAMP expression, osteocalcin expression, and bone mineralization capacity for osteoblast lineage cells. 2. The method of claim 1, wherein said portion of the isolated component cells comprise osteoclast lineage cells, which are stimulated to differentiate prior to the step of assaying. 3. The method of claim 2, wherein the cells of said subset are osteoclast precursors. 4. The method according to claim 1, wherein the tissue is calvarial bone and the subset of cells are osteoblast lineage cells. 5. The method according to claim 1, wherein the tissue is bone narrow. 6. The method according to claim 5, wherein the cells of said subset are osteoblast lineage cells. 7. The method according to claim 5, wherein the cells of said subset are osteoclast precursors. 8. An immortalized p53-deficient mouse osteoblast lineage cell line wherein cells of said cell line exhibit a set of differentiation markers including alkaline phosphatase expression, parathyroid hormone-induced cAMP expression, osteocalcin expression, and bone mineralization capacity. 9. An immortalized p53-deficient mouse osteoclast lineage cell line wherein cells of said cell line exhibit a set of differentiation markers including Mac-1 expression and nonalkaline phosphatase expression and wherein upon induction of cells of said cell line to differentiate said cells produce mouse osteoclast cells, said osteoclast cells exhibiting a set of differentiation markers including calcitonin receptor expression, tartrate resistant acid phosphatase expression, and bone resorptive activity. 10. Mouse osteoclast cells characterized by a set of differentiation markers including calcitonin receptor expression, tartrate resistant acid phosphatase expression, and bone resorptive activity produced by inducing the cell line of claim 9 to differentiate.

Details for Patent 5,683,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26